EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Original Research: Biomarker Testing in a Canadian Centre for Patients with Non‑small Cell Lung Cancer: Assessing Residual Risks

Yunting Liu, Steven Shen, Manav Shukla, Janet Malowany, Shaheed Hakim, Zared Aziz, David N. Parente, Victoria Cheung, Suneil Khanna, Yoo-Joung Ko, Wondwossen Kidanewold, Michael A. Ko und 2 weitere

Canadian Oncology Today · 2025

DOI: 10.58931/cot.2025.2342 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Canadian Oncology Today, 2025. Verfasst von Yunting Liu und 13 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Biomarker testing is critical for guiding treatment decisions and clinical management in patients with non-small cell lung cancer (NSCLC). Although the clinical utility of comprehensive testing for point mutations and gene rearrangements is well established, access to next-generation sequencing (NGS)‑based assays in Ontario has historically been limited due to provincial funding constraints. We conducted a retrospective chart review of 215 patients diagnosed with lung adenocarcinoma over a five-year period (2016-2021) and report the observed biomarker testing practice. Testing primarily comprised polymerase chain reaction (PCR)-based detection of common epidermal growth factor receptor (EGFR) mutations and immunohistochemistry (IHC) for anaplastic lymphoma kinase (ALK) overexpression, with or without confirmatory fluorescence in situ hybridization (FISH), and programmed death-ligand 1 (PD-L1) IHC. IHC for ROS1 overexpression, as a surrogate for ROS1 fusion, was observed in the first quarter of 2020. Routine panel-based NGS testing was implemented in the first quarter of 2021. Noting the differences between PCR- and NGS-based EGFR assessment, risks of “false negative” were estimated based on Bayesian analyses. Given the limited scope of PCR tests in terms of variants detected, the post-test, residual risk of “false negative” EGFR was estimated to range ~1:90 in white, Caucasian patients, to ~1:9 in Asian patients. We observed consistent implementation of EGFR, ALK, and PD-L1 testing during the study period, which was in alignment with 2017 National Comprehensive Cancer Network (NCCN) guideline recommendations. However, the delayed adoption of ROS1 testing and NGS-based profiling, including assays for MET and RET alterations, reflects broader limitations in provincial funding policy and highlights the need for equitable access to comprehensive biomarker testing in Ontario.

Zitieren

APA

Liu, Y., Shen, S., Shukla, M., Malowany, J., Hakim, S., Aziz, Z., Parente, D. N., Cheung, V., Khanna, S., Ko, Y., Kidanewold, W., Ko, M. A., Thu, K. L., & Yoon, J. (2025). Original Research: Biomarker Testing in a Canadian Centre for Patients with Non‑small Cell Lung Cancer: Assessing Residual Risks. Canadian Oncology Today. https://doi.org/10.58931/cot.2025.2342

Vancouver

Liu Y, Shen S, Shukla M, Malowany J, Hakim S, Aziz Z, et al. Original Research: Biomarker Testing in a Canadian Centre for Patients with Non‑small Cell Lung Cancer: Assessing Residual Risks. Canadian Oncology Today. 2025. doi:10.58931/cot.2025.2342

BibTeX
@article{Liu2025,
  author = {Liu, Yunting and Shen, Steven and Shukla, Manav and Malowany, Janet and Hakim, Shaheed and Aziz, Zared and Parente, David N. and Cheung, Victoria and Khanna, Suneil and Ko, Yoo-Joung and Kidanewold, Wondwossen and Ko, Michael A. and Thu, Kelsie L. and Yoon, Ju-Yoon},
  title = {Original Research: Biomarker Testing in a Canadian Centre for Patients with Non‑small Cell Lung Cancer: Assessing Residual Risks},
  journal = {Canadian Oncology Today},
  year = {2025},
  doi = {10.58931/cot.2025.2342}
}
Kostenlos starten →